BLASUBCUTANEOUSINJECTABLEPriority Review
Approved
Jun 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
ILARIS (canakinumab) by Novartis is anti-human il-1β antibody of the igg1/κ isotype. Approved for the following autoinflammatory periodic fever syndromes: cryopyrin-associated periodic syndromes (caps) ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (caps), older, hyperimmunoglobulin d (hyper-igd) syndrome (hids)/mevalonate kinase deficiency (mkd) in adult and 4 more indications. First approved in 2009.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ILARIS (canakinumab) is a fully human monoclonal antibody that specifically binds and neutralizes IL-1β, a key driver of inflammation in autoinflammatory diseases. It is indicated for rare genetic autoinflammatory periodic fever syndromes (CAPS, HIDS/MKD, FMF), active Still's disease, and systemic juvenile idiopathic arthritis. The drug works by blocking IL-1β activity without affecting IL-1α or IL-1 receptor antagonist, thereby reducing the excessive inflammasome-driven immune response characteristic of these conditions.
$39.0MPart D
LOE ApproachingStable
Product is approaching loss of exclusivity with modest Part D spending (~$39M), signaling a mature, specialty-focused franchise with smaller commercial team opportunities.
Mechanism of Action
anti-human IL-1β antibody of the IgG1/κ isotype. Canakinumab binds to human IL-1β and neutralizes its activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1α or IL-1 receptor antagonist (IL-1ra). CAPS refer to rare genetic syndromes generally caused by mutations in the…
Worked on ILARIS at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.